Ustekinumab Stops Joint Damage in Psoriatic Arthritis Ustekinumab Stops Joint Damage in Psoriatic Arthritis

In a pooled analysis of data from the PSUMMIT studies, ustekinumab slowed progression of joint damage at week 24, which persisted out to 2 years. Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Rheumatology News Source Type: news